Diabetes

Labs Like Premier Medical Laboratory Services Now Seeing Increased Demand for Various Molecular Diagnostic Tests

~As social distancing measures have decreased, demand for medical tests other than COVID-19 increase~

GREENVILLE, SC September 23, 2020  – At the onset of the pandemic the nation began to practice social distancing, and subsequently, many stopped scheduling visits with their doctors. Laboratories like Premier Medical Laboratory Services suddenly pivoted much of their efforts into providing a high volume of testing for COVID-19. Now, as more businesses and schools have reopened, less of the population has continued to practice extreme social distancing measures. Accordingly, more patients are visiting their physicians’ offices again for routine check-ups and other healthcare needs other than the Coronavirus.

With this, PMLS, recently named one of the Top Genetic Diagnostic Companies of 2020, says that they are beginning to see a rise in demand for tests that they offer to address various medical diagnostic needs aside from COVID-19. Some of these tests included are their pharmacogenomics, advanced cardiovascular testing, and their women’s health & wellness and diabetes panels.

“We are continuing to process up to 50,000 COVID-19 tests per day, but are glad to see an increase in orders for the other tests we provide,” said Kevin Murdock founder of Premier Medical Laboratory Services. “We know that our tests offer vital insight to physicians so that they can best plan the proper care for their patients.”

Including their portfolio of COVID-19 assays, all of PMLS’ tests processed at their 40,000 sqft laboratory are performed with the latest in science and technology to provide the most advanced and comprehensive testing results. For example, PMLS’s MDDiabeticPro panel includes the revolutionary DIABETESpredict test, which is a first of its kind predictive genetic test for type 2 diabetes developed in collaboration with world leading doctors and scientists of Harvard and MIT. The DIABETESpredict test is expected to mark a new era in diabetes prevention and care through evaluating the risk of the disease onset by examining individual genetic profiles and is currently only available to the US through PMLS.

PMLS’s cardiovascular panel, MDHeartPro, offers a more complete look at a patient’s cardiovascular health than the standard lipid profile that is commonly ordered.  In addition to the standard lipid panel, MDHeartPro includes tests that identify plaque buildup, lipid particle size, hereditary factors, and other advanced risk factors.

At PMLS’s fully COLA and CLIA regulated laboratory many of their processes are automated with cutting-edge laboratory equipment. Using a cloud based-laboratory information management system, OnGen, PMLS communicates real-time results to physicians directly from their lab equipment. Because of this, PMLS is able to process hundreds of thousands of COVID-19 tests per month while increasing the testing capacity for their other molecular diagnostic offerings without compromising accuracy or their quick turnaround time of results.

Tagged , , , , , , ,

GlycoMark®, Inc. Announces Partnership with Premier Medical Laboratory Services to Expand Diabetes Test Menu

New York, NY. Sept. 25th, 2018 – GlycoMark®, Inc. has announced a partnership with Premier Medical Laboratory Services (PMLS) to increase the availability of the GlycoMark test, the only FDA-cleared blood test specific to detecting recent hyperglycemia and hyperglycemic excursions in patients with diabetes. With the partnership, PMLS will promote and offer the GlycoMark test to its network of physicians through its sales organization and MD DiabeticPro® laboratory services.

“As an industry leader, we strive to provide physicians with innovative solutions that enable the best possible care for patients,” said Melanie Stallings, Director of Laboratory Operations of Premier Medical Laboratory Services. “We believe that the GlycoMark test provides important additional information to help physicians personalize patient treatment plans and drive better clinical outcomes.”

Hyperglycemia, which leads to numerous diabetic vascular complications, isn’t always easily detected. Nearly 40% of patients who are deemed to be in “good control”, based on A1C glucose averages, may have significant postprandial hyperglycemia or glycemic variability. Furthermore, a periodic blood glucose is not always reliably timed or performed, and may yield inaccurate results.

“We are very pleased with our partnership with Premier Medical Laboratory. By adding the GlycoMark test to PMLS’s MD DiabeticPro menu, physicians will have increased awareness and access to the test to help improve the management of patients with diabetes,” said Hiro Ishibashi, President of GlycoMark, Inc.

ABOUT GLYCOMARK

GlycoMark, Inc., based in Manhattan, New York, is dedicated to improving the management and health of patients with diabetes. The company is a joint venture among Toyota Tsusho America, Inc. (New York, NY), Toyota Tsusho Corporation (Tokyo, Japan), and Nippon Kayaku Co., Ltd. (Tokyo, Japan), and is the exclusive supplier of the GlycoMark test in the U.S., Europe, Australia, Indonesia and the Middle East. The GlycoMark test is the only FDA cleared non-fasting blood test that detects hyperglycemia and hyperglycemic excursions occurring in the prior 1 to 2 weeks. Since its discovery, the GlycoMark Test, a quantitative test for 1,5-Anhydroglucitol (1,5-AG), has been described in more than 1,300 scientific and medical publications and is shown to be independently associated with complications of diabetes. More information is available at www.GlycoMark.com.

ABOUT PREMIER MEDICAL LABORATORY

Premier Medical is a highly complex, advanced diagnostic lab with multiple specialty programs and a full complement of chemistry, immunoassay and hematology testing, located in Greenville, SC.

With our partnership with GlycoMark, we would like to announce our new test panel:

  • MD DiabeticPro
  • Glucose w eAG
  • Hemoglobin A1C
  • GlycoMark
  • Hemoblobin A1C/GlycoMark Ratio
  • Adiponectin
  • Insulin
  • C-Peptide

PMLS also offers the following specialty tests, to provide clinicians with clinically relevant testing in order to improve patient outcomes and quality of life:

  • MD HeartPro – An advanced cardiovascular profile that identifies hidden risk factors not identified by common cardiovascular testing
  • MD AllergyPro – Serum based IgE testing
  • MD DrugPro – A Medication Compliance Monitoring toxicology program
  • MD WellnessPro – A comprehensive look at a patient’s wellness profile
  • MD GeneticPro – Premier Medical’s constantly growing molecular department’s menu includes
      • Pharmacogenomics
      • Hereditary Cancer Panels
      • Women’s Health Vaginitis/Vaginosis/STI panel
      • Respiratory Pathogen Panel
      • Gastrointestinal Pathogen Panel
      • Hepatitis C Genotyping

GlycoMark is a registered trademark of GlycoMark, Inc. MD DiabeticPro is a registered trademark of Premier Medical Laboratory.

 

MEDIA CONTACT

Lauren Lehman, Marketing and Partner Relations

lauren_lehman@glycomark.com

Tagged , , , , , , , ,